



FEP Medical Policy Manual

FEP 7.01.21 Reduction Mammoplasty for Breast-Related Symptoms

Effective Policy Date: July 1, 2023

Original Policy Date: March 2012

Related Policies:

None

Reduction Mammoplasty for Breast-Related Symptoms

Description

Description

Macromastia, or gigantomastia, is a condition that describes breast hyperplasia or hypertrophy. Macromastia may result in clinical symptoms such as shoulder, neck, or back pain, or recurrent intertrigo in the mammary folds. In addition, macromastia may be associated with psychosocial or emotional disturbances related to the large breast size. Reduction mammoplasty is a surgical procedure designed to remove a variable proportion of breast tissue to address emotional and psychosocial issues and/or to relieve the associated clinical symptoms.

OBJECTIVE

The objective of this evidence review is to evaluate the clinical situations where the evidence demonstrates that reduction mammoplasty improved the net health outcome.

POLICY STATEMENT

Reduction mammoplasty may be considered **medically necessary** for the treatment of macromastia when well-documented clinical symptoms are present, including but not limited to:

- Documentation of a minimum 6-week history of shoulder, neck, or back pain related to macromastia not responsive to conservative therapy, such as an appropriate support bra, exercises, heat/cold treatment, and appropriate nonsteroidal anti-inflammatory agents or muscle relaxants; OR
- Recurrent or chronic intertrigo between the pendulous breast and the chest wall.

Reduction mammoplasty is considered **investigational** for all other indications not meeting the above criteria.

POLICY GUIDELINES

The presence of shoulder, neck, or back pain is the most common stated *medical* rationale for reduction mammoplasty. However, because these symptoms and others may be subjective, Plans have implemented various patient selection criteria designed to be more objective. These criteria include:

- Use of photographs, providing a visual documentation of breast size or documenting the presence of shoulder grooving, an indication that the breast weight results in grooving of the bra straps on the shoulder.
- Requirement of a specified amount of breast tissue to be resected, commonly 500 to 600 grams per breast.
- Use of the Schnur Sliding Scale, which suggests a minimum amount of breast tissue to be removed for the procedure to be considered medically necessary, based on the patient's body surface area. Some Plans may use the Schnur Sliding Scale only for weight of resected tissue that falls below 500 to 600 grams.
- Requirement that the patient must be within 20% of ideal body weight to eliminate the possibility that obesity is contributing to the symptoms of neck or back pain.

BENEFIT APPLICATION

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

Medical policies regarding reduction mammoplasty have focused on the distinction between a cosmetic procedure, performed primarily to improve the appearance of the breast, and a medically necessary procedure, performed primarily to relieve documented clinical symptoms. It should be noted that the emotional and psychosocial distress associated with body appearance does not constitute a *medical* rationale for reduction mammoplasty, and thus these indications would be considered cosmetic.

Determinations of whether a proposed therapy would be considered reconstructive or cosmetic should always be interpreted in the context of the specific benefits language. State or federal mandates may also dictate coverage decisions.

The requirement for the presence of functional impairment as a coverage criterion for a specific etiology may vary from Plan to Plan. It should be noted that, in general, the presence of functional impairment would render its treatment medically necessary and thus not subject to contractual definitions of reconstructive or cosmetic.

FDA REGULATORY STATUS

Reduction mammoplasty is a surgical procedure and, as such, is not subject to regulation by the U.S. Food and Drug Administration.

RATIONALE

Summary of Evidence

For individuals who have symptomatic macromastia who receive reduction mammoplasty, the evidence includes systematic reviews, randomized controlled trials, cohort studies, and case series. Relevant outcomes are symptoms and functional outcomes. Studies have indicated that reduction mammoplasty is effective at decreasing breast-related symptoms such as pain and discomfort. There is also evidence that functional limitations related to breast hypertrophy are improved after reduction mammoplasty. These outcomes are achieved with acceptable complication rates. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

SUPPLEMENTAL INFORMATION

Practice Guidelines and Position Statements

The purpose of the remaining sections in Supplemental Information is to provide reference material regarding existing practice guidelines and position statements, U.S. Preventive Services Task Force Recommendations and Medicare National Coverage Decisions and registered, ongoing clinical trials. Inclusion in the Supplemental Information does not imply endorsement and information may not necessarily be used in formulating the evidence review conclusions.

Guidelines or position statements will be considered for inclusion in Supplemental Information if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American Society of Plastic Surgeons

In 2011, the American Society of Plastic Surgeons (ASPS) issued practice guidelines and a companion document on criteria for third-party payers for reduction mammoplasty.^{21,22} This guideline was updated and reaffirmed in March 2021. Based on high quality evidence, the ASPS strongly recommends that "postmenarche female patients presenting with breast hypertrophy should be offered reduction mammoplasty surgery as first-line therapy over nonoperative therapy based solely on the presence of multiple symptoms rather than resection weight." The guideline goes on to state that "reduction mammoplasty surgery is considered standard of care for symptomatic breast hypertrophy." The companion document notes that medical records should document the symptoms associated with the hypertrophy the patient has experienced, and lists the following:

- "Documentation may include pain that patient experiences in the neck, back, or breasts related to movement
- Difficulties in daily activities such as grocery shopping, banking, using transportation, preparing meals, feeding, showering, etc
- Documentation of any secondary complications or infections that may have occurred as a result of hypertrophy or macromastia including intertrigo, chronic rash, cervicalgia, dorsalgia, or kyphosis
- Documentation of prior procedures or therapies may be included but not required for approval
- Photographs demonstrating the patient's breast appearance, possible shoulder grooves and kyphosis can be included in the medical documentation
- Significant scientific evidence supports non-operative therapies should not be required prior to approval of the procedure."

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

REFERENCES

1. Dabbah A, Lehman JA, Parker MG, et al. Reduction mammoplasty: an outcome analysis. *Ann Plast Surg.* Oct 1995; 35(4): 337-41. PMID 8585673
2. Schnur PL, Schnur DP, Petty PM, et al. Reduction mammoplasty: an outcome study. *Plast Reconstr Surg.* Sep 1997; 100(4): 875-83. PMID 9290655
3. Hidalgo DA, Elliot LF, Palumbo S, et al. Current trends in breast reduction. *Plast Reconstr Surg.* Sep 1999; 104(3): 806-15; quiz 816; discussion 817-8. PMID 10456536
4. Glatt BS, Sarwer DB, O'Hara DE, et al. A retrospective study of changes in physical symptoms and body image after reduction mammoplasty. *Plast Reconstr Surg.* Jan 1999; 103(1): 76-82; discussion 83-5. PMID 9915166
5. Collins ED, Kerrigan CL, Kim M, et al. The effectiveness of surgical and nonsurgical interventions in relieving the symptoms of macromastia. *Plast Reconstr Surg.* Apr 15 2002; 109(5): 1556-66. PMID 11932597
6. Iwuagwu OC, Walker LG, Stanley PW, et al. Randomized clinical trial examining psychosocial and quality of life benefits of bilateral breast reduction surgery. *Br J Surg.* Mar 2006; 93(3): 291-4. PMID 16363021
7. Sabino Neto M, Dematt MF, Freire M, et al. Self-esteem and functional capacity outcomes following reduction mammoplasty. *Aesthet Surg J.* 2008; 28(4): 417-20. PMID 19083555
8. Iwuagwu OC, Platt AJ, Stanley PW, et al. Does reduction mammoplasty improve lung function test in women with macromastia? Results of a randomized controlled trial. *Plast Reconstr Surg.* Jul 2006; 118(1): 1-6; discussion 7. PMID 16816661
9. Saarniemi KM, Keranen UH, Salminen-Peltola PK, et al. Reduction mammoplasty is effective treatment according to two quality of life instruments. A prospective randomised clinical trial. *J Plast Reconstr Aesthet Surg.* Dec 2008; 61(12): 1472-8. PMID 17983882
10. Schnur PL, Hoehn JG, Ilstrup DM, et al. Reduction mammoplasty: cosmetic or reconstructive procedure?. *Ann Plast Surg.* Sep 1991; 27(3): 232-7. PMID 1952749
11. Schnur PL. Reduction mammoplasty-the schnur sliding scale revisited. *Ann Plast Surg.* Jan 1999; 42(1): 107-8. PMID 9972729
12. Singh KA, Losken A. Additional benefits of reduction mammoplasty: a systematic review of the literature. *Plast Reconstr Surg.* Mar 2012; 129(3): 562-570. PMID 22090252
13. Torresetti M, Zuccatosta L, Di Benedetto G. The effects of breast reduction on pulmonary functions: A systematic review. *J Plast Reconstr Aesthet Surg.* Dec 2022; 75(12): 4335-4346. PMID 36229312
14. Hernanz F, Fidalgo M, Muoz P, et al. Impact of reduction mammoplasty on the quality of life of obese patients suffering from symptomatic macromastia: A descriptive cohort study. *J Plast Reconstr Aesthet Surg.* Aug 2016; 69(8): e168-73. PMID 27344408
15. Kerrigan CL, Collins ED, Kim HM, et al. Reduction mammoplasty: defining medical necessity. *Med Decis Making.* 2002; 22(3): 208-17. PMID 12058778
16. Thibaudeau S, Sinno H, Williams B. The effects of breast reduction on successful breastfeeding: a systematic review. *J Plast Reconstr Aesthet Surg.* Oct 2010; 63(10): 1688-93. PMID 19692299
17. Chen CL, Shore AD, Johns R, et al. The impact of obesity on breast surgery complications. *Plast Reconstr Surg.* Nov 2011; 128(5): 395e-402e. PMID 21666541
18. Shermak MA, Chang D, Burette K, et al. Increasing age impairs outcomes in breast reduction surgery. *Plast Reconstr Surg.* Dec 2011; 128(6): 1182-1187. PMID 22094737
19. Gust MJ, Smetona JT, Persing JS, et al. The impact of body mass index on reduction mammoplasty: a multicenter analysis of 2492 patients. *Aesthet Surg J.* Nov 01 2013; 33(8): 1140-7. PMID 24214951
20. Nelson JA, Fischer JP, Chung CU, et al. Obesity and early complications following reduction mammoplasty: an analysis of 4545 patients from the 2005-2011 NSQIP datasets. *J Plast Surg Hand Surg.* Oct 2014; 48(5): 334-9. PMID 24506446
21. American Society of Plastic Surgeons. Reduction Mammoplasty: ASPS Recommended Insurance Coverage Criteria for Third-Party Payers. 2021; <https://www.plasticsurgery.org/documents/Health-Policy/Reimbursement/insurance-2021-reduction-mammoplasty.pdf>. Accessed December 13, 2022.
22. Perdakis G, Dillingham C, Boukovalas S, et al. American Society of Plastic Surgeons Evidence-Based Clinical Practice Guideline Revision: Reduction Mammoplasty. *Plast Reconstr Surg.* Mar 01 2022; 149(3): 392e-409e. PMID 35006204

POLICY HISTORY - THIS POLICY WAS APPROVED BY THE FEP® PHARMACY AND MEDICAL POLICY COMMITTEE ACCORDING TO THE HISTORY BELOW:

Date	Action	Description
March 2012	New policy	
March 2013	Replace policy	Policy updated with literature review; references 14, 19-20 and 23 added; Policy statements unchanged
March 2014	Replace policy	Policy updated with literature review; no references added; Policy statements unchanged
March 2015	Replace policy	Policy updated with literature review; references 20-21 added; reference 13 deleted. Policy statement added indicating reduction mammoplasty is considered not medically necessary for all other indications not meeting medically necessary criteria.
March 2017	Replace policy	Policy updated with literature review; references 14 and 22 added; Policy statements unchanged
June 2018	Replace policy	Policy updated with literature review through December 11, 2017; no references added; a citation removed as out-of-scope and references. Policy statements unchanged except not medically necessary statement corrected to "investigational".
June 2019	Replace policy	Policy updated with literature review through December 6, 2018; no references added; reference 20 updated. Policy statements unchanged.
June 2020	Replace policy	Policy updated with literature review through November 27, 2019; no references added. Policy statements unchanged.
June 2021	Replace policy	Policy updated with literature review through December 10, 2020; no references added. Policy statements unchanged.
December 2021	Replace policy	Off-cycle editorial update to policy statement only: "OR" added to first policy statement to clarify intent, which was unchanged: "Documentation of a minimum 6-week history of shoulder, neck, or back pain related to macromastia not responsive to conservative therapy, such as an appropriate support bra, exercises, heat/cold treatment, and appropriate nonsteroidal anti-inflammatory agents or muscle relaxants "
June 2022	Replace policy	Policy updated with literature review through November 15, 2021; no references added. Policy statements unchanged.
June 2023	Replace policy	Policy updated with literature review through December 13, 2022; references added. Policy statements unchanged.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.